Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

The Chemours Company CC

Basic Materials — Specialty Chemicals
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.49
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — 7 —
Sell — — — — — — — — — — — —
Insider Ownership
1.47%

Capital & Financial Ratios

Market Cap
2,170.00
Revenue
5,797.00
Net Income
(305.00)
Free Cash Flow
218.00
Net Debt
3,201.00
Current Ratio
1.66
Debt/Equity
(80.67)
P/E ratio
0.00
P/S ratio
0.37
P/B ratio
0.00
Past 5Y EPS Growth
(1.34%)
This Y EPS Growth
6.63%
Next Y EPS Growth
93.55%
Next 5Y EPS Growth
34.96%
in millions of $

Dividends

Payout Ratio
0.18
Annual Dividend Rate
1.00
Annual Dividend Yield
3.32%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 0.35
—
—
—
2025 0.51
—
—
—
—
2024 1.00
—
—
—
—
2023 1.00
—
—
—
—
2022 1.00
—
—
—
—
2021 1.00
—
—
—
—
2020 1.00
—
—
—
—
2019 1.00
—
—
—
—
2018 0.84
—
—
—
—
2017 0.12
—
—
—
—
2016 0.12
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1,807.00 713.00 672.00 671.00
Receivables 610.00 770.00 679.00 907.00
Inventory 1,352.00 1,463.00 1,569.00 1,452.00
Other — — 1.00 1.00
3,835.00 3,017.00 3,001.00 3,094.00
2023 2024 2025 Q'26
Payables 1,159.00 1,156.00 954.00 937.00
ST’ Debt 51.00 54.00 42.00 34.00
Other 218.00 214.00 184.00 207.00
2,486.00 1,820.00 1,686.00 1,861.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1,381.00 1,591.00 — —
—
’25 1,368.00 1,615.00 1,495.00 1,330.00
5,808.00
’24 1,362.00 1,554.00 1,508.00 1,358.00
5,782.00
’23 1,536.00 1,643.00 1,487.00 1,412.00
6,078.00
’22 1,764.00 1,915.00 1,777.00 1,375.00
6,831.00
’21 1,436.00 1,655.00 1,680.00 1,574.00
6,345.00
’20 1,305.00 1,093.00 1,233.00 1,338.00
4,969.00
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (44.00) 158.00 — —
—
’25 (112.00) 93.00 146.00 137.00
264.00
’24 (290.00) (620.00) 139.00 138.00
(633.00)
’23 (124.00) 67.00 131.00 482.00
556.00
’22 2.00 291.00 301.00 161.00
755.00
’21 39.00 256.00 311.00 208.00
814.00
’20 44.00 111.00 299.00 353.00
807.00
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (93.00) 114.00 — —
—
’25 (196.00) 50.00 112.00 85.00
51.00
’24 (389.00) (693.00) 63.00 26.00
(993.00)
’23 (215.00) 9.00 183.00 209.00
186.00
’22 (104.00) 229.00 229.00 127.00
481.00
’21 (21.00) 189.00 244.00 125.00
537.00
’20 (62.00) 50.00 252.00 300.00
540.00
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.19) (1.81) — —
—
’25 (0.03) (2.54) 0.40 (0.31)
(2.56)
’24 0.34 0.46 (0.18) (0.05)
0.57
’23 0.96 (2.52) 0.13 (0.12)
(1.60)
’22 1.43 1.26 1.52 (0.64)
3.65
’21 0.57 0.39 1.27 1.40
3.60
’20 0.61 0.15 0.46 0.11
1.32

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 22.56 22.88 15.10 9.13 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.95 39.05 32.70 20.12 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,600 6,200 6,000 5,700 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.04 0.98 0.96 1.02 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,831.00 6,078.00 5,782.00 5,808.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.66% 21.42% 19.75% 15.53% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 741.00 (318.00) 106.00 (277.00) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.85% (5.23%) 1.83% (4.77%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 578.00 (252.00) 69.00 (386.00) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 300.00 318.00 360.00 351.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.97 40.82 38.68 38.66 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.72 (1.60) 0.58 (2.57) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.86 3.73 (4.23) 1.76 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.76) (2.48) (2.41) (1.42) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.10 1.25 (6.64) 0.34 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.13 4.96 3.83 1.67 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 155.36 148.91 149.49 150.24 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 8.41 0.00 28.64 0.00 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.70 0.78 0.44 0.31 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.30 6.40 4.42 7.06 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.07 1.15 1.03 0.90 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.15 37.44 (5.97) 102.75 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 755.00 556.00 (633.00) 264.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (274.00) (370.00) (360.00) (213.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 481.00 186.00 (993.00) 51.00 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,323.00 1,349.00 1,197.00 1,315.00 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,633.00 4,038.00 4,113.00 4,141.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,531.00 2,231.00 3,400.00 3,469.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,107.00 739.00 572.00 251.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.61% (3.18%) 0.88% (5.18%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.26% (5.16%) 5.02% (1.08%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 52.81% (27.41%) 10.53% (93.80%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Chemours Company (CC), a specialty chemicals leader in TiO2, fluoroproducts, and performance materials, exemplifies the sector’s boom-bust cycles since its 2015 DuPont spin-off. Revenue peaked at $6.83 billion in 2022 amid pricing power but plunged 15% to $5.78 billion in 2023-2024 due to TiO2 oversupply from China, weak construction demand, and PFAS litigation costs, compressing gross margins below 20% and swinging net income from $578 million profit to -$237 million loss. Despite elevated debt near $4 billion and recent negative free cash flow, operational resilience shines through stabilizing shares and insider buying— including notable purchases by the CFO, an executive, and CEO in 2025—signaling confidence in a turnaround.

Analysts forecast modest revenue recovery (3% CAGR to $6.32 billion by 2027) tied to U.S. infrastructure spending and green transitions, with EPS rebounding from a projected 2025 loss to $2.28 in 2027. Yet profitability volatility persists, with ROE and ROIC swings underscoring leverage risks in a high-capex environment pressured by regulations and geopolitical tensions like China’s market dominance.

At current levels trading above consensus targets, Chemours sits at a pivotal crossroads: undervalued cyclically with macro tailwinds from reshoring and Fed easing, but vulnerable to litigation reserves and slowdowns. For investors eyeing industrial revival, this leveraged play warrants close scrutiny amid insider optimism and execution on debt discipline.

Read full commentary →

The Chemours Company (CC) Latest News

News by impact score

Fine-tune

17 Sep

4 , 6:09 AM
Chemours agreed to a $455 million PFAS settlement that may alter perceptions of its ongoing environmental liabilities. The $455 million PFAS settlement directly reduces Chemours' long-term environmental liabilities and could improve its market valuation.

16 Sep

3 , 12:52 AM
Chemours (CC) trims losses but core demand keeps slipping. Slipping core demand signals ongoing revenue pressure that can moderately affect Chemours financial trajectory.

11 Sep

4 www.manufacturingdive.com, 8:30 AM
Chemours, DuPont and Corteva agreed to a $455 million settlement with North Carolina to resolve PFAS contamination claims. The large settlement creates direct financial pressure and sustained regulatory exposure for Chemours on core PFAS operations.

10 Sep

4 , 7:00 AM
DuPont, Chemours and Corteva reached an agreement to resolve PFAS-related claims in North Carolina. Resolution of PFAS claims reduces major legal liabilities and uncertainty for Chemours.

4 , 6:45 AM
Chemours, DuPont and Corteva reached an agreement to resolve PFAS-related claims in North Carolina. Agreement resolves major PFAS litigation and reduces ongoing legal and financial uncertainties for Chemours.

3 investorshub.advfn.com, 10:13 AM
Chemours settles North Carolina PFAS claims for $455 million, prompting 6% share price increase. Large settlement resolves litigation overhang yet requires major cash payment that affects near-term finances without shifting core operations.

3 Sep

4 , 8:06 AM
Chemours (CC) launches new refrigerants for AI cooling applications. New refrigerants target AI cooling and mark strategic entry into high-growth tech sector.

14 Aug

4 , 10:22 AM
Chemours expands its low-GWP refrigerant portfolio for data centers. Portfolio expansion targets high-growth data center cooling demand with regulatory push for low-GWP products.

11 Aug

3 transcript www.fool.com, 8:16 PM
Chemours (CC) released its Q2 2026 earnings call transcript covering quarterly financial results, operational updates, and forward outlook. Quarterly earnings details can shift near-term sentiment and valuations but rarely redefine long-term strategy.

10 Aug

4 , 6:45 AM
Chemours launches Opteon ZE and Opteon 515B refrigerants for chiller applications powering data centers, commercial buildings, and mission critical environments. New product launches target high-growth data center markets and can materially lift Chemours revenue and positioning.

3 , 1:28 PM
UBS notes larger destocking in Chemours' refrigerant business, reducing certainty around medium-term growth. Refrigerant destocking adds measurable uncertainty to Chemours' medium-term growth path.

5 Aug

4 www.fool.com, 4:37 PM
Chemours shares plunged Wednesday after the company cut full-year guidance citing weaker demand for titanium dioxide and fluoroproducts plus higher costs. Guidance cut and demand weakness point to material near-term pressure on revenue and margins.

4 app.moby.co, 8:30 AM
The Chemours Company held its Q2 2026 earnings call and released related financial details and outlook. Q2 earnings details and guidance directly move valuation and investor positioning for the company.

3 transcript www.marketbeat.com, 5:04 PM
Chemours Q2 earnings call highlights company financial results, operational updates and forward guidance. Quarterly earnings data can shift near-term investor sentiment and valuation metrics.

3 , 3:02 PM
Chemours Co highlighted strategic portfolio review and TSS progress during its Q2 2026 earnings call. Strategic portfolio review may moderately influence financial performance and competitive positioning.

4 Aug

3 , 7:00 PM
Chemours (CC) missed Q2 earnings and revenue estimates. Q2 earnings and revenue miss signals weaker financial performance likely to pressure stock valuation and investor sentiment.

3 , 4:30 PM
The Chemours Company released second quarter financial results. Quarterly results deliver updated performance data that can shift near-term investor views without altering long-term strategy.

29 Jul

3 , 1:08 AM
Chemours (CC) flagged earnings beat signals combined with valuation shift may alter the prior bull case for the stock. Earnings signals and valuation adjustment introduce moderate influence on Chemours future performance and sentiment.

28 Jul

3 , 10:00 AM
Chemours (CC) expected to beat earnings estimates, prompting questions on whether to buy the stock. Earnings beat expectations may moderately influence short-term Chemours stock performance and sentiment.

2 Jul

4 , 2:13 PM
Chemours reaches long-term PFAS settlement that may alter investment case for the company. Long-term PFAS settlement creates major ongoing financial and legal exposure for Chemours.

26 Jun

4 , 11:30 AM
Chemours agrees to pay $450 million to settle forever chemicals pollution claims in North Carolina, but state officials reject the deal as inadequate. The $450 million settlement creates a substantial financial liability plus ongoing regulatory pressure that can materially affect Chemours' cash flow and operations.

25 Jun

3 Insider Monkey, 9:33 PM
JPMorgan raised its view on Chemours (CC). JPMorgan analyst upgrade may lift short-term Chemours investor sentiment and share price.

3 Zacks, 8:36 AM
New fire contracts improve earnings visibility and support a positive PRM stock outlook tied to The Chemours Company (CC). New contracts provide better earnings visibility that can moderately lift near-term sentiment and performance.

24 Jun

4 www.cbsnews.com, 11:55 AM
Chemours will pay $450 million in the first federal settlement over forever chemicals. $450 million settlement creates major financial liability and raises risk of further regulatory costs.

3 MT Newswires, 11:37 AM
Chemours will pay a $22.5 million penalty and implement relief programs to resolve environmental claims involving forever chemicals. Penalty imposes direct financial cost and requires operational changes for environmental compliance.

3 PR Newswire, 10:43 AM
Chemours reaches agreement with U.S. EPA to resolve PFAS claims. Settlement resolves regulatory uncertainty but imposes costs that moderately affect financial performance.

9 May

4 www.marketbeat.com, 1:12 PM
Chemours Q1 earnings call highlights key financial results, operational updates, strategic initiatives, and forward guidance for the chemical company. Q1 earnings highlights reveal financial performance and guidance that significantly sway investor sentiment and stock trajectory.

8 May

4 Simply Wall St., 9:39 AM
The Chemours Company reported a surprise loss in its results, prompting analysts to issue new forecasts. Surprise loss and revised analyst forecasts indicate significant pressure on financial performance and investor sentiment.

7 May

4 GlobeNewswire, 7:27 AM
Data Center Liquid Cooling Fluids Market forecast to 2032 predicts growth driven by rising demand for environmentally friendly fluid technology and expansion in DTC liquid cooling, positively impacting The Chemours Company (CC). Market growth forecast to 2032 in data center liquid cooling fluids directly supports Chemours' position in environmentally friendly technologies.

3 Zacks, 8:06 AM
Chemours' Q1 earnings beat analyst estimates, but revenues missed expectations. Q1 earnings beat signals operational strength, but revenue miss introduces caution, yielding moderate impact on future performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us